RU2317973C2 - Способ получения общего количества фенольной кислоты из шалфея многокорневого (даньшеня) и ее применение - Google Patents

Способ получения общего количества фенольной кислоты из шалфея многокорневого (даньшеня) и ее применение

Info

Publication number
RU2317973C2
RU2317973C2 RU2004136577/04A RU2004136577A RU2317973C2 RU 2317973 C2 RU2317973 C2 RU 2317973C2 RU 2004136577/04 A RU2004136577/04 A RU 2004136577/04A RU 2004136577 A RU2004136577 A RU 2004136577A RU 2317973 C2 RU2317973 C2 RU 2317973C2
Authority
RU
Russia
Prior art keywords
total amount
column
phenol acid
water
eluted
Prior art date
Application number
RU2004136577/04A
Other languages
English (en)
Other versions
RU2004136577A (ru
Inventor
Фэн ВЭЙ (CN)
Хоншуи ЮЭ (CN)
Декунь ЛИ (CN)
Чжансюэ СУНЬ (CN)
Дженл н ЙЕ (CN)
Сю ЛИ (CN)
Original Assignee
Tjan Tszin Tasli Farmas Jutikl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tjan Tszin Tasli Farmas Jutikl filed Critical Tjan Tszin Tasli Farmas Jutikl
Publication of RU2004136577A publication Critical patent/RU2004136577A/ru
Application granted granted Critical
Publication of RU2317973C2 publication Critical patent/RU2317973C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2004136577/04A 2002-05-23 2003-05-21 Способ получения общего количества фенольной кислоты из шалфея многокорневого (даньшеня) и ее применение RU2317973C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB021179239A CN1202103C (zh) 2002-05-23 2002-05-23 丹参总酚酸的制备方法
CN02117923.9 2002-05-23

Publications (2)

Publication Number Publication Date
RU2004136577A RU2004136577A (ru) 2005-06-27
RU2317973C2 true RU2317973C2 (ru) 2008-02-27

Family

ID=29426731

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004136577/04A RU2317973C2 (ru) 2002-05-23 2003-05-21 Способ получения общего количества фенольной кислоты из шалфея многокорневого (даньшеня) и ее применение

Country Status (13)

Country Link
US (1) US7641922B2 (ru)
EP (1) EP1506951B9 (ru)
JP (1) JP4570461B2 (ru)
KR (1) KR101004660B1 (ru)
CN (1) CN1202103C (ru)
AT (1) ATE424379T1 (ru)
AU (1) AU2003242135B8 (ru)
CA (1) CA2486378C (ru)
DE (1) DE60326450D1 (ru)
DK (1) DK1506951T3 (ru)
ES (1) ES2326165T3 (ru)
RU (1) RU2317973C2 (ru)
WO (1) WO2003099759A1 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2529491C2 (ru) * 2009-03-30 2014-09-27 ТАСЛИ ФАРМАСЬЮТИКАЛ ГРОУП Ко., Лтд. Соединение сальвианоловой кислоты л, способ его приготовления и применения
RU2668955C2 (ru) * 2013-08-29 2018-10-05 Тасли Фармасьютикал Груп Ко., Лтд. Новое соединение сальвианоловой кислоты т, способ его получения и его применение

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100339085C (zh) 2003-09-23 2007-09-26 天津天士力制药股份有限公司 治疗心脑血管疾病的中药组合物
CN102579460B (zh) * 2003-12-30 2015-04-29 麦仁斯有限公司 用增强代谢活性的丹参衍生物治疗肥胖和代谢综合症
CN100372525C (zh) * 2004-06-01 2008-03-05 广东天之骄生命科技有限公司 一种复方丹参冻干粉针剂及其制备方法
JP2010180250A (ja) * 2004-07-30 2010-08-19 Iskra Ind Co Ltd 最終糖化産物生成抑制剤
JP4633572B2 (ja) * 2004-07-30 2011-02-16 イスクラ産業株式会社 糖尿病改善剤
JP4868199B2 (ja) * 2004-09-10 2012-02-01 学校法人鈴鹿医療科学大学 サルビアノール酸ｂを有効成分とする神経幹細胞増殖剤
JP2006232698A (ja) * 2005-02-23 2006-09-07 Suzuka Univ Of Medical Science サルビアノール酸ｂ等を主成分とする脳卒中又は脳卒中後遺症の予防用又は治療用薬剤
WO2006115321A1 (en) * 2005-04-25 2006-11-02 Industry Academic Cooperation Foundation, Yeungnam University Composition comprising the extract of salvia miltiorrhiza bge showing enhancing activity for the prevention or treatment of blood circulatory disease.
CN1919251B (zh) * 2005-08-24 2010-11-03 天津天士力制药股份有限公司 治疗心血管疾病的中药组合物
CN1919240B (zh) * 2005-08-24 2011-02-16 天津天士力制药股份有限公司 治疗心脑血管疾病的中药
KR100725839B1 (ko) * 2005-10-06 2007-12-11 일성신약주식회사 단삼으로부터 분리된 탄시논류의 화합물을 함유하는인지기능 장애의 예방 및 치료용 조성물
KR20070040209A (ko) * 2005-10-11 2007-04-16 일성신약주식회사 단삼 분획물을 함유하는 인지기능 장애의 예방 및 치료용 조성물
CN101210002B (zh) * 2006-12-27 2011-04-20 中国科学院大连化学物理研究所 一种丹酚酸b化学对照品的分离制备方法
CN101721468B (zh) * 2008-10-21 2013-02-13 天津天士力之骄药业有限公司 一种丹参总酚酸制备方法
CN101401843B (zh) * 2008-11-18 2011-10-05 阳国平 一种中药丹参有效成分的提取方法
CA2807283C (en) * 2010-08-06 2019-05-14 Xijun Yan Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease
CN107951981A (zh) * 2017-12-30 2018-04-24 黄旭东 一种筋骨伤涂剂及其制备方法
CN112315997B (zh) * 2020-11-30 2022-03-25 四川省中医药科学院 一种丹参和葛根提取物的固体分散体及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000069296A (ko) * 1996-12-05 2000-11-25 윌리암 제이.하트만 항바이러스 활성을 갖는 살비아 종의 추출물
US6043276A (en) * 1998-06-25 2000-03-28 Georgetown University School Of Medicine Compounds obtained from salvia species having antiviral activity
CN1129572C (zh) * 1998-09-11 2003-12-03 中国科学院上海药物研究所 丹参多酚酸盐混合物及其制备方法和用途
US6299910B1 (en) * 1999-04-07 2001-10-09 Techical Sourcing International, Inc. Methods for identification, purification, and manufacturing of the active constituent in Salvia-miltiorrhiza (dansheng) and the application of this product in enhancing cardiovascular functions
CN1163227C (zh) 1999-04-19 2004-08-25 上海中医药大学 丹酚酸b镁盐在制备治疗慢性肝病药剂中的应用
CN1229324C (zh) 2001-09-26 2005-11-30 中国医学科学院药物研究所 丹参总酚酸的提取方法及其制剂的制法与用途
CN1161317C (zh) 2001-09-27 2004-08-11 华东理工大学 从植物丹参中提取纯化丹参素的方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2529491C2 (ru) * 2009-03-30 2014-09-27 ТАСЛИ ФАРМАСЬЮТИКАЛ ГРОУП Ко., Лтд. Соединение сальвианоловой кислоты л, способ его приготовления и применения
RU2668955C2 (ru) * 2013-08-29 2018-10-05 Тасли Фармасьютикал Груп Ко., Лтд. Новое соединение сальвианоловой кислоты т, способ его получения и его применение

Also Published As

Publication number Publication date
ES2326165T3 (es) 2009-10-02
WO2003099759A8 (fr) 2004-03-11
AU2003242135B8 (en) 2009-12-03
CA2486378A1 (en) 2003-12-04
AU2003242135B2 (en) 2009-08-27
CN1459448A (zh) 2003-12-03
WO2003099759A1 (fr) 2003-12-04
KR20050024281A (ko) 2005-03-10
CA2486378C (en) 2011-02-22
DE60326450D1 (de) 2009-04-16
US20050159491A1 (en) 2005-07-21
AU2003242135A1 (en) 2003-12-12
DK1506951T3 (da) 2009-05-25
CN1202103C (zh) 2005-05-18
RU2004136577A (ru) 2005-06-27
EP1506951B1 (en) 2009-03-04
EP1506951A1 (en) 2005-02-16
JP4570461B2 (ja) 2010-10-27
JP2005538055A (ja) 2005-12-15
US7641922B2 (en) 2010-01-05
ATE424379T1 (de) 2009-03-15
KR101004660B1 (ko) 2011-01-03
EP1506951B9 (en) 2009-08-26
EP1506951A4 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
RU2317973C2 (ru) Способ получения общего количества фенольной кислоты из шалфея многокорневого (даньшеня) и ее применение
US20040018261A1 (en) Method and use of extract of a member of Typhaceae's family
CN102670696A (zh) 杜仲叶提取物及其制备方法和应用
CN105175266A (zh) 一种从咖啡豆中提取绿原酸和咖啡酸的方法
CN104257882A (zh) 一种从枸杞渣粕同时提取分离油脂、绿原酸和总黄酮的方法
CN102078341A (zh) 高纯度银杏黄酮及组合物
CN106832045A (zh) 一种银杏外种皮同时提取果胶和酚酸类化合物的方法
CN109287665A (zh) 一种银杏酚酸-阿维菌素复合杀虫剂及其制备方法
KR100945778B1 (ko) 꽈배기모자반 추출물의 구성성분 및 그 제조방법, 꽈배기모자반 추출물을 포함하는 혈관확장제 및 꽈배기모자반 추출물의 구성성분을 포함하는 혈관확장제
CN104000935B (zh) 一种从马铃薯皮渣中提取抗氧化酚酸的方法
CN1318440C (zh) 低酸银杏叶提取物的制备方法
CN109453234B (zh) 桑白皮制品及其制备方法
CN106581108A (zh) 一种脱除人参提取物中残留农药霜霉威的方法
CN103372034A (zh) 银杏叶提取物的制备方法
CN106860489A (zh) 一种杨梅叶多酚的提取方法
CN107582582A (zh) 一种提取纯化辣木黄酮的工艺
CN112062870B (zh) 一种具有美白保湿活性的多糖、含有该多糖的美白保湿面霜及其制备方法
CN1739744A (zh) 一种黄酮类化合物粉剂的生产方法
CN106880652A (zh) 一种芒果叶多酚的提取方法
CN107915742B (zh) 一种银杏二萜内酯的提取分离方法
CN110721128B (zh) 桑白皮提取物及其制备方法
CN113908184A (zh) 一种艾草提取物的提取工艺
KR20020015805A (ko) 메밀로부터 고순도 천연 루틴의 추출방법
JPH04182434A (ja) いちょう葉抽出物を取得する方法
JPH03227985A (ja) イチョウ葉からフラボノイドを高含有する抽出物の簡易な製造法

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner